Back to today’s briefing

Story perspectives

FDA Approves Moderna's RSV Vaccine for High-Risk Adults

6/13/2025

28 4

Summary

Story summary

The FDA has granted expanded approval for Moderna's RSV vaccine, mRNA-1345 (mRESVIA), now available for high-risk adults aged 18-59. This pivotal decision, revealed on June 12, 2025, comes after a successful Phase 3 study demonstrated strong immune responses, paving the way for protection during the upcoming 2025-2026 respiratory virus season.

1 of 1

Story summary

The FDA has granted expanded approval for Moderna's RSV vaccine, mRNA-1345 (mRESVIA), now available for high-risk adults aged 18-59. This pivotal decision, revealed on June 12, 2025, comes after a successful Phase 3 study demonstrated strong immune responses, paving the way for protection during the upcoming 2025-2026 respiratory virus season.